Neuroblastoma Advanced Therapies Center

Opportunities for Research Participation

Physicians and researchers from the Neuroblastoma Advanced Therapies Center at Cincinnati Children’s offer clinical research studies for patients with neuroblastoma.

View a complete list of current clinical trials or narrow your search specifically for those related to neuroblastomas.

Therapy for Release

• ADVL1211: A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents with Recurrent or Refractory Solid Tumors, Including CNS Tumors
• NANT2009-03: A Phase I/II Study of MLN8237 in Combination with Irinotecan and Temozolomide for patients with relapsed or refractory Neuroblastoma
• 131-I-MIBG: Expanded Access:  An Open Label, Expanded Access Protocol Using I-Metaiodobenzylguanidine (131I-MIBG) Therapy in Patients With Refractory Neuroblastoma
• ADVL1011: INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease
• ADVL1014: A Phase 1 Dose Escalation Study of Reolysin, a Replication Competent Reovirus, in Pediatric Patients With Relapsed or Refractory Solid Tumors
• ADVL0911: A Phase 1 Dose Escalation Study of Seneca Valley Virus (NTX-010), A Replication-Competent Picornavirus, in Relapsed/Refractory Pediatric Patients With Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features
• ADVL0912: A Phase I/II study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-MET, in children with Relapsed/Refractory Solid Tumors, Primary CNS Tumors, and Anaplastic Large Cell Lymphoma
• ADVL0921: A Phase II Study of MLN8237 (IND# 102984), a Selective Aurora A Kinase Inhibitor in Children with Recurrent/Refractory Solid Tumors and Leukemias  
• NANT 2008-02: Phase I Study of Vorinostat in Combination With 13-Cis-Retinoic Acid in Patients With Refractory/Recurrent Neuroblastoma
• NANT 2007-03: Vorinostat With 131I-MIBG Therapy for Resistant/Relapsed Neuroblastoma: A Phase I Study
• NANT 2004-04: Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb (LXS) Oral Powder In Patients with Recurrent or Resistant Neuroblastoma
• NANT 2007-02: Bevacizumab, Cyclophosphamide, and Zoledronic Acid in Treating Patients with Recurrent or Refractory High-Risk Neuroblastoma
• NANT 99-02: Modulation of Intensive Melphalan (L-PAM) by Buthionine Sulfoximine (BSO) with Autologous Stem Cell Support for Recurrent High-Risk Neuroblastoma (A Phase I Study).
• HSV1716: A Phase I Dose Escalation Study of Intratumoral Herpes Simplex Virus-1 Mutant HSV1716 In Patients with Refractory Non-Central Nervous System (Non-CNS) Solid Tumors